Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,647,431 papers from all fields of science
Search
Sign In
Create Free Account
Gilteritinib
Known as:
6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide
An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Narrower (1)
ASP2215
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Gilteritinib Likely New Standard Care for AML.
Cancer Discovery
2019
Corpus ID: 91188217
Final results from the phase III ADMIRAL trial indicate that the FLT3/AXL tyrosine kinase inhibitor gilteritinib extends overall…
Expand
2019
2019
PS1036 UPDATED RESULTS FROM A PHASE 1 STUDY OF GILTERITINIB IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED AML
K. Pratz
,
M. Cherry
,
+10 authors
E. Bahceci
HemaSphere
2019
Corpus ID: 196573007
2019
2019
Benefits With Gilteritinib for AML Were Maintained, Regardless of Co-Mutations
L. Lawrence
2019
Corpus ID: 195387915
The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial…
Expand
2019
2019
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Lisa A. Raedler
,
Rph
2019
Corpus ID: 195423935
2019
2019
Neue AML-Risikodefinition hat Kinderleben gerettet
F. Klein
InFo Hämatologie + Onkologie
2019
Corpus ID: 189111916
Charakteristika der „neuen“ FLT-3-Inhibitoren Crenolanib ist ein starker Typ-1-Inhibitor, der gegen FLT3-ITD und FLT3-D835…
Expand
2019
2019
Gilteritinib prolongs survival in patients with FLT3-mutated R/R AML: phase 3 ADMIRAL trial results
Hisayuki Yokoyama
2019
Corpus ID: 219849231
2019
2019
PS1024 IMPACT OF MINIMAL RESIDUAL DISEASE AND COMPLETE REMISSION (CR)/CR WITH PARTIAL HEMATOLOGIC RECOVERY ON SURVIVAL AFTER GILTERITINIB THERAPY IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML
M. Levis
,
A. Perl
,
+11 authors
E. Bahceci
HemaSphere
2019
Corpus ID: 196510991
2019
2019
Safety and tolerability of gilteritinib plus azacitidine in patients with newly diagnosed AML
G. Yoshimoto
2019
Corpus ID: 216564799
2018
2018
Abstract 805: NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML
M. Ciomei
,
E. Ardini
,
+11 authors
A. Isacchi
Experimental and Molecular Therapeutics
2018
Corpus ID: 80941676
FLT3, KIT and CSF1R are members of the class III receptor tyrosine kinase family, characterized by an autoinhibitory…
Expand
2017
2017
The FLT3 Inhibitor Gilteritinib Has Activity in Patients with AML.
Cancer Discovery
2017
Corpus ID: 34179951
Gilteritinib was well tolerated in a phase I/II dose-escalation and dose-expansion study.